

**Pediatrics · Educational evidence summary**

Anticholinergic exposure and dry mouth in children

This pediatric review addresses anticholinergic exposure and dry mouth in children.

UnifiedACB · Published October 3, 2026 · Updated October 4, 2026

[Read the current article](#)

<https://unifiedacb.com/articles/080-anticholinergic-exposure-and-dry-mouth-in-children/>

Dry mouth needs a specific explanation

A child's complaint of a dry mouth, a caregiver's observation, and a medicine's anticholinergic classification are three different pieces of information. They may be related, but none substitutes for the others. These questions explain how to discuss oral symptoms without assuming that a burden score has established the cause or the right treatment.

Is dry mouth just an inconvenience?

Saliva contributes to oral health and functions such as chewing and swallowing. NIDCR describes medicines as one possible cause of reduced saliva and emphasizes the importance of oral assessment and care. [NIDCR: dry mouth](#)

That general information supports taking the symptom seriously. It does not quantify the effect of a particular medicine in a child or show that an anticholinergic mechanism is the only explanation. The symptom's duration, impact, and clinical context remain important.

Does a dry mouth prove high anticholinergic burden?

No. A symptom cannot be used to reverse-engineer a source category. The category comes from the original publication and its method; the symptom comes from the child's experience or assessment. A high category does not prove the symptom will occur, and an absent source row does not invalidate it.

The review should record both accurately. If they appear inconsistent, the next step is to examine the clinical history and product-specific evidence, not to alter the source value until it agrees with the observation.

What if reducing saliva is the intended treatment goal?

Some medicines are used for a saliva-related indication. Glycopyrrolate oral-solution labeling includes treatment of chronic severe drooling in specified pediatric patients with neurological



conditions. It also describes unwanted effects, including overly dry mouth. [DailyMed: glycopyrrolate oral solution](#)

This creates a question about the balance of intended benefit and unwanted experience. A burden badge cannot determine that balance. The clinician needs the actual product, use pattern, response, and symptom history rather than a general class statement alone.

What should the symptom history include?

Describe what the child reports and what caregivers observe, keeping the sources distinct. Note timing, change from baseline, and effects on eating, speaking, or comfort when relevant. Avoid assuming that a behavior or feeding change represents dry mouth without assessment.

The medication history should include recent changes and actual occasional use. A product listed in the record may not have been used during the period of concern, while a nonprescription product may be missing from the list.

Can a pediatric cognition review reassure us about oral symptoms?

It cannot answer that question directly. Cognitive testing and dry-mouth outcomes are different measurements. A study can report no adverse cognitive association while leaving oral symptoms unmeasured. The conclusion should stay attached to the outcome actually studied.

The reverse is also true: dry mouth does not establish cognitive impairment or predict an adult-like long-term outcome. Using one finding to fill another evidence gap creates certainty that the research does not provide.

Does a Beers tag apply to the child?

The geriatric criteria discussed elsewhere on the site retain their older-adult scope. They should not be used as a pediatric treatment rule or a substitute for the child's product-specific evidence. An absent tag also does not establish pediatric safety.

The correct interpretation separates original source classifications, age-appropriate product information, and the child's clinical assessment. Each contributes different information to the discussion.

A symptom record can distinguish persistent dryness from an occasional observation and describe its effect on eating, speaking, sleep, or oral care. These details are useful to the treating clinician and dental team. They should remain descriptive: the number of affected activities is not a validated anticholinergic burden score, and it should not be converted into one.

Should the medicine be changed?

That requires a discussion with the treating clinician, and sometimes dental assessment, based on the symptom and treatment purpose. This article does not recommend stopping, reducing, or



substituting a medicine. A burden category cannot determine whether an alternative provides the same benefit.

The useful next step is a precise record of the oral concern and current products, followed by an assessment that considers both symptom burden and the reason treatment is used. That approach keeps uncertainty visible while taking the child's experience seriously.

References

1. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2023;71:2052-2081. [Source](#)
2. Vennard O, Stewart C, Tolia M, Soiza RL, Myint PK. Anticholinergic Medication Burden Scales: A Systematic Review. J Am Geriatr Soc. 2026;74(6):1771-1784. [Source](#)
3. Feinstein JA, et al. Anticholinergic Medications and Parent-Reported Anticholinergic Symptoms in Neurologically Impaired Children. J Pain Symptom Manage. 2023;65(2):e109-e114. [Source](#)
4. Hong IS, Bishop JR. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother. 2010;44(7-8):1171-1180. [Source](#)
5. Ghezzi E, Chan M, Kalisch Ellett LM, et al. The effects of anticholinergic medications on cognition in children: a systematic review and meta-analysis. Sci Rep. 2021;11:219. [Source](#)
6. National Institute of Dental and Craniofacial Research. Dry Mouth. Patient and professional health information. [Source](#)
7. DailyMed. Glycopyrrolate oral solution: prescribing information. National Library of Medicine. Sections on indications, warnings, adverse reactions, and pediatric use. [Source](#)

Explore the evidence

[Ask UnifiedACB](#) about a medication or source, browse the [Medication Library](#), or read the [methodology](#).

Disclosure

Funding: None. Conflict of interest: None declared for the UnifiedACB educational project.

Educational evidence summary. This content does not provide patient-specific medical advice and does not replace clinical judgment, medication reconciliation, or prescribing guidance.